SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Kirk's Market Thoughts -- Ignore unavailable to you. Want to Upgrade?

To: #Breeze who wrote (19040)5/29/2024 3:22:37 PM
From: Kirk ©  Read Replies (2) | Respond to of 26709
 
Thanks. Now our targets agree.

Here is a longer-term chart showing considerable resistance 28 to 30, but if they can deliver fundamentals (cancer cures) with some of the Phase 2 studies, it could be fun to hold for another run at the red line.

So far, its 200-dma turned the surge so a correction to the low or its 50-dma wouldn't be a surprise.

That all assumes they don't run out of money which is a concern every year.




To: #Breeze who wrote (19040)11/25/2024 10:14:36 AM
From: Kirk ©  Read Replies (2) | Respond to of 26709
 
Dead cat bounce for AGEN or an opportunity now that it seems to have turned?

I don't follow many of these high-risk stocks that are bleeding cash to make new drugs so is this common for the sector or AGEN specific?

.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News